NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Deferoxamine

Last Revision: April 20, 2020.

Estimated reading time: 2 minutes

CASRN: 70-51-9

image 134971977 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

Deferoxamine is poorly absorbed orally, so it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants.[1] Although Australian guidelines recommend against breastfeeding during deferasirox treatment,[2] these were published before case reports of infants being safely breastfed by a mother with beta-thalassemia receiving deferoxamine and finding of no changes of iron in breastmilk. Limited information indicates that maternal doses of deferoxamine up to 2 grams daily do not affect iron levels in breastmilk and did not cause any adverse effects in two breastfed infants.[3] Some experts advocate breastfeeding in women receiving deferoxamine for iron overload caused by beta-thalassemia.[4][3] However, since little published information is available on the use of deferoxamine during breastfeeding, monitoring of the infant's serum iron is recommended.

Drug Levels

Maternal Levels. A woman with beta-thalassemia restarted deferoxamine 2 grams subcutaneously daily for 5 days per week 3 days after delivery. Milk was collected on days 5 and 9 postpartum and 11 weeks postpartum. Iron levels in milk were 0.7, 10.4 and 4.8 micromoles/L, respectively (normal range 7.7 to 22.4 micromoles/L).[2]

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

A woman with beta-thalassemia restarted deferoxamine 2 grams subcutaneously 5 days per week 3 days after delivery. She breastfed (extent not stated) one of her twins from birth. After 17 days of breastfeeding, the infant's serum levels were as follows: iron 17.4 micromoles/L, ferritin 200 mcg/L, and transferrin16.8 micromoles/L, all in the normal range. Serum urea, calcium and magnesium were also normal. The second twin was hospitalized for longer and breastfeeding status in the hospital was not reported. Both infants were breastfed (extent not stated) for 4 months postpartum. Both had normal neurologic and motor development at 4 months and laboratory values consistent with their heterozygous beta-thalassemia: hemoglobin F 11.1% and 8.4%, hemoglobin 10.5 g/L and 10.5 g/L, reticulocytes 3.3% and 2.6%, and median erythrocyte volume 60 fL and 58 fL. Their serum levels of iron, ferritin, transferrin, liver enzymes, plasma urea and bilirubin were all normal.[2]

A woman with beta-thalassemia gave birth to an infant by cesarean section and breastfed her infant (extent not stated) from birth while receiving deferoxamine (dosage not stated). No adverse effects were reported in her infant.[4]

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Deferasirox

References

1.
Jensen CE, Tuck SM, Wonke B. Fertility in beta thalassaemia major: a report of 16 pregnancies, preconceptual evaluation and a review of the literature. Br J Obstet Gynaecol. 1995;102:625–9. [PubMed: 7654640]
2.
Ho PJ, Tay L, Lindeman R, et al. Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias. Intern Med J. 2011;41:516–24. [PubMed: 21615659]
3.
Surbek DV, Glanzmann R, Nars PW, et al. Pregnancy and lactation in homozygous beta-thalassemia major. J Perinat Med. 1998;26:240–3. [PubMed: 9773387]
4.
Pafumi C, Zizza G, Caruso S, et al. Pregnancy outcome of a transfusion-dependent thalassemic woman. Ann Hematol. 2000;79:571–3. [PubMed: 11100748]

Substance Identification

Substance Name

Deferoxamine

CAS Registry Number

70-51-9

Drug Class

Breast Feeding

Lactation

Chelating Agents

Iron Chelating Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Related information

Similar articles in PubMed

  • Review Deferasirox[Drugs and Lactation Database (...]
    Review Deferasirox
    . Drugs and Lactation Database (LactMed). 2006
  • Review Iohexol[Drugs and Lactation Database (...]
    Review Iohexol
    . Drugs and Lactation Database (LactMed). 2006
  • Review Ioxaglate[Drugs and Lactation Database (...]
    Review Ioxaglate
    . Drugs and Lactation Database (LactMed). 2006
  • Review Iopromide[Drugs and Lactation Database (...]
    Review Iopromide
    . Drugs and Lactation Database (LactMed). 2006
  • Review Iopamidol[Drugs and Lactation Database (...]
    Review Iopamidol
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...